Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection

by Maria Raffaella Ambrosio, Giulia De Falco, Alessandro Gozzetti, Bruno Jim Rocca, Teresa Amato, Vasileios Mourmouras, Sara Gazaneo, Lucia Mundo, Veronica Candi, Pier Paolo Piccaluga, Maria Grazia Cusi, Lorenzo Leoncini, and Stefano Lazzi

Haematologica 2014 [Epub ahead of print]

doi:10.3324/haematol.2014.111872

Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
Plasmablastic transformation of a pre-existing plasma cytoma: a possible role for reactivation of Epstein Barr virus infection

Maria R. Ambrosio¹, Giulia De Falco¹, Alessandro Gozzetti³, Bruno J. Rocca¹, Teresa Amato¹, Vasileios Mourmouras¹, Sara Gazaneo¹, Lucia Mundo¹, Veronica Candi³, Pier P. Piccaluga¹, Maria G. Cusi⁵, Lorenzo Leoncini¹ and Stefano Lazzi⁶

¹Department of Medical Biotechnologies, Section of Pathology, University of Siena - Siena (SI), Italy; ²School of Biological and Chemical Sciences, Queen Mary University of London, UK; ³Hematology Unit, Azienda Ospedaliera Universitaria Senese – Siena (SI), Italy; ⁴Molecular Pathology Laboratory, Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University Medical School – Bologna (BO), Italy; ⁵Department of Medical Biotechnologies, Infectious Diseases Section University of Siena - Siena (SI), Italy; ⁶Section of Pathology, Azienda Ospedaliera Universitaria Senese – Siena (SI), Italy

Correspondence
Professor Lorenzo Leoncini, MD; Department of Medical Biotechnologies, Section of Pathology, University of Siena – Via delle Scotte, 6 – 3100 Siena (SI), Italy. E-mail: leoncinil@unisi.it
To the Editor,

The distinction between plasmablastic lymphoma (PBL) and plasmacytoma may be confidently accomplished on the basis of histopathological and clinical features. However, some cases can be challenging owing to a morphological overlap. The main significant differences include genetic aberrations [i.e. t(11;14); t(4;14), hyperdiploidy], and in particular the presence of Epstein-Barr virus (EBV)-encoded RNA (EBER), which is positive in 75-100% of all PBL cases, in contrast to plasmacytoma (10% of cases).\(^1\) The exact role of EBV in the pathogenesis of PBL is still poorly understood.\(^2\) Although it has been suggested that PBL may occur as a high grade transformation from a pre-existing plasmacytoma following EBV infection, this concept has not been well established and definitive proof is lacking.\(^3,4\)

In December 2011, a 74-year old man presented for a right maxillary sinus solitary mass, infiltrating the oral cavity. Histological examination of the bioptic specimen showed a uniform proliferation of plasma cells with abundant cytoplasm, round eccentrically located nuclei and clock-face chromatin without nucleoli (Figure 1A). Neoplastic cells expressed CD38, CD138, CD79a, MUM-1; they were restricted for immunoglobulin heavy chain G (IgG) and light chain lambda (Ig\(\lambda\)). CD20 and PAX-5 were negative. The proliferative index (Ki-67) was about 10%. A complete work-up with computer tomography (CT)-scan and bone marrow biopsy excluded other sites of involvement; therefore, the final diagnosis was extra-osseous plasmacytoma. The patient was treated with one cycle of chemotherapy with Bortezomib 1,3 mg/m\(^2\) day 1,4,8,11; Melphalan 9 mg/m\(^2\) day 1-4, and Prednisone 50 mg/day 1,4, 8,11 (VMP scheme), obtaining a 90% reduction of the mass; subsequently, a 50 Gy of involved field radiotherapy treatment led to a complete remission, which was confirmed at CT/positron emission tomography. Ten months later, the patient relapsed. The histological evaluation of the surgical specimen confirmed the previous diagnosis; however, an increase in the proliferative index was detected (Ki-67 about 40%). The patient was treated newly with Bortezomib associated with cyclophosphamide 500 mg day 1,8, and dexamethasone 20 mg day 1,4,8,11, achieving only a minimal response. Thus, he switched to a third line therapy with lenalidomide 25 mg day 1,21, cyclophosphamide 750 mg day 1,8 and dexamethasone 20 mg every week (RCD scheme), obtaining an excellent but short response with a rapid growing of the mass in May 2013. The patient underwent surgical excision of the neoplastic lesion; laboratory tests showed haemoglobin 13.9 g/dl, white blood cell count 8,320/mm\(^3\), platelet 408,000/mm\(^3\). The histological examination of the specimen showed a diffuse and cohesive monomorphic proliferation of round- to oval-shaped large cells with scant cytoplasm, and prominent nucleoli (Figure 1D). Neoplastic cells were CD38, CD138 and MUM-1 positive, IgG/\(\lambda\) restricted, and CD20, CD79a, and PAX5 negative. The proliferative index (Ki-67) was about 95%.
EBER was present in 90% of the neoplastic cells (Figure 1E). All of the neoplastic cells expressed the MYC protein. FISH analysis by using dual-color break-apart probes did not identify any of the known translocations involving the MYC gene. To evaluate whether we deal with the transformation of the pre-existing plasmacytoma, CD56 and cyclin D1 positivity was checked in all the specimens. Both plasmacytomas and plasmablastic samples expressed CD56, whereas no cyclin D1 staining was identified. In addition, IGH-VDJ rearrangement was performed in all the specimens according to BIOMED-2 protocol by using framework region 1 (FR-1) and JH regions (VHFR1-JH) primers. A productive IGHV rearrangement (VH3-23, DH3-22, JH4*02) with a 93.27% of identity of germline sequence was detected, thus confirming the clonal relationship of all the samples (Figure 1C, F). The final diagnosis was plasmablastic transformation of pre-existing plasmacytoma of the oral cavity. The patient was treated with liposomal doxorubicin 50 mg/m² day 1 and cytosine arabinoside 2 g day 1-2, obtaining a minimal response. Thus, bendamustine 90 mg/m² day 1-2 for 2 cycles was administrated with no response.

Since EBV reactivation has been observed following bortezomib therapy, EBV was hypothesized as the trigger responsible for the transformation of plasmacytoma in PBL, determining the multiple rapid relapses of the disease. Therefore, we checked EBV also in the plasmacytoma samples; interestingly, in these cases, only a small percentage of tumor cells with blastic appearance were EBER-positive increasing from the first (10%) to the second (30%) biopsy (Figure 1B). In addition, the first sample was negative for MYC, whereas in the second specimen 30% of the neoplastic cells expressed the protein. Since the oncogenic role of EBV is controversial and the type of viral program expressed by plasmablastic lymphoma is still a matter of debate, a complete genetic assessment of the virus latency and lytic genes by RT-qPCR and immunohistochemistry was performed. The expression of EBNA1 and the negativity for LMP-1 and EBNA-2 in all the three biopsies suggested a type I latency (Figure 1G). In the third biopsy, we detected expression of some genes/proteins involved in the lytic cycle (BZLF1, BMRF1, BHRF1 coding for the Zebra, Ea-D and Ea-R/p17 proteins, respectively) (Figure 1H- I). The fact that we did not find BLLF1- gp350/220 expression, suggests an abortive lytic cycle in neoplastic cells. It is known that the reactivation of lytic cycle may play a role in EBV-driven lymphomagenesis by increasing the total number of latently infected cells. In addition, viral lytic genes, or cellular genes induced by viral lytic proteins could potentially encode paracrine factors that promote tumor growth. A number of physiological stimuli and chemical agents may favour the lytic form of EBV infection, including B-cell receptor stimulation, transforming growth factor-beta, hypoxia and DNA damage. Since no response has been obtained by conventional therapy and considering the high viral load in the blood (264,000 DNA copies/ml), the same therapy of post transplant lymphoproliferative disorders (PTLD) was
performed. Accordingly, rituximab 375 mg/m² weekly for three doses and acyclovir were added to a continuous lenalidomide treatment day 1-28 per month at 15 mg/day, to increase potential response, to reduce the reservoir of latently infected cells, and to decrease viral burden. Emerging data has suggested that rituximab may have therapeutic value also in patients with tumours which do not express CD20 by eliminating reactive B-lymphocytes in the microenvironment that may support the growth and survival of neoplastic cells. Depleting reactive B-cells may also enhance the anti-lymphoma immune response. As far as the rationale of using acyclovir is concerned, recent data on nasopharyngeal carcinoma and glioblastoma indicate that antiviral drugs may improve outcomes in viral-associated tumors by inhibiting lytic replication.

In our case, the therapy induced a marked reduction of the mass, in parallel to viral load decrease (12,250 DNA copies/ml) (Figure 2A-B). At the last follow-up (eleven months later), the patient was in complete remission.

In conclusion, the paramount highlights of our case consists on drawing the attention in two main issues. First of all, it should be underlined that MYC protein expression can occur also in the absence of MYC translocation and may probably be due to alternative mechanisms, likely involving microRNAs (miRNA) dysregulation. In our case, a down-regulation of some miRNAs known to regulate MYC expression (i.e. has-miR34b, hsa-miR155, has-miRlet 7a, has-miR-29a and -29b) has been detected, in comparison to normal lymph node and to MYC translocation-positive Burkitt lymphoma cases (Figure 3). This finding may explain the up-regulation of MYC in the absence of the MYC translocation. On the other hand, pathologist should take into consideration the possibility of staining all plasmacytomas and probably all plasma cell myelomas for EBV, in order to identify those patients at higher risk of transformation to PBL, which require a totally different and more aggressive therapeutic protocol and a closer follow-up. In those patients in which plasmacytoma de-differentiate to PBL, the therapeutic regimens used in PTLD to reduce the reservoir of latently infected cells and to inhibit lytic replication should be taken into account to improve the prognosis.

Enhanced understanding of the multiple mechanisms regulating EBV reactivation will, hopefully, lead to the development of minimally toxic, highly specific therapies. The use of routine chemotherapy in combination with acyclovir appears to be a promising approach for treating patients with EBV-positive tumors.

AUTHORSHIP AND DISCOSURES
MRA and GDF wrote the paper and designed the experimental approach; AG and VC recruited the patient; BJR and VM evaluated the immunohistochemical findings; TA, SG and LM performed the laboratory work; PPP, MGC and SL provided their expertise and contributed with fruitful discussion; LL co-ordinated the work

The authors have no conflicting interests to declare
References


**Figure Legends**

**Figure 1. Morphologic features of the samples.** (A) A uniform population of plasma cells with abundant cytoplasm, round eccentrically located nuclei and clock-face chromatin without nucleoli is observed. (B) A small percentage of tumor cells are EBER-positive. (C) Neoplastic population is characterized by monoclonal IGHV rearrangement. (D) Histological specimen shows a diffuse and cohesive proliferation of round- to oval-shaped large cells with scant cytoplasm, and prominent nucleoli. (E) EBER positivity is observed in 90% of the neoplastic cells. (F) The same IGHV rearrangement of the plasmacytoma samples is shown. (G) EBNA1, and (H) Ea-D and (I) Ea-R expression in blastic cells of the plasmablastic lymphoma sample is present. [A, D: Haematoxylin and Eosin; B, E: EBER in situ hybridization; G: EBNA1 stain; H: Ea-D stain; I: Ea-R stain. A-B, D-E, G-I: original magnification: 20x]

**Figure 2. Head computed tomography findings.** A reduction of the mass is observed between the first (A) and the second (B) head computed tomography (arrows).

**Figure 3. microRNAs relative expression level.** In plasmablastic sample a down-regulation of has-miR34b, hsa-miR155, has-miRlet 7a, has-miR-29a and -29b is detected, in comparison to normal lymph node and to MYC translocation-positive Burkitt lymphoma cases.